

Published in final edited form as:

*Mol Genet Metab Rep.* 2014 ; 1: 103–113. doi:10.1016/j.ymgmr.2014.02.002.

## Biochemical and Physiological Improvement in a Mouse Model of Smith-Lemli-Opitz Syndrome (SLOS) Following Gene Transfer with AAV Vectors

Lee Ying, Xavier Matabosch, Montserrat Serra, Berna Watson, Cedric Shackleton, and Gordon Watson

Children's Hospital Oakland Research Institute, 5700 Martin Luther King Jr. Way, Oakland, Ca 94609, USA

### Abstract

Smith-Lemli-Opitz syndrome (SLOS) is an inborn error of cholesterol synthesis resulting from a defect in 7-dehydrocholesterol reductase (DHCR7), the enzyme that produces cholesterol from its immediate precursor 7-dehydrocholesterol. Current therapy employing dietary cholesterol is inadequate. As SLOS is caused by a defect in a single gene, restoring enzyme functionality through gene therapy may be a direct approach for treating this debilitating disorder. In the present study, we first packaged a human DHCR7 construct into adeno-associated virus (AAV) vectors having either type-2 (AAV2) or type-8 (AAV2/8) capsid, and administered treatment to juvenile mice. While a positive response (assessed by increases in serum and liver cholesterol) was seen in both groups, the improvement was greater in the AAV2/8-DHCR7 treated mice. Newborn mice were then treated with AAV2/8-DHCR7 and these mice, compared to mice treated as juveniles, showed higher DHCR7 mRNA expression in liver and a greater improvement in serum and liver cholesterol levels. Systemic treatment did not affect brain cholesterol in any of the experimental groups. Both juvenile and newborn treatments with AAV2/8-DHCR7 resulted in increased rates of weight gain indicating that gene transfer had a positive physiological effect.

### Keywords

Smith-Lemli-Opitz syndrome (SLOS); 7-dehydrocholesterol reductase (DHCR7); gene therapy; AAV; cholesterol synthesis

---

© 2014 Elsevier Inc. All rights reserved.

Corresponding Author: Gordon Watson, Children's Hospital Oakland Research Institute, 5700 Martin Luther King Way, Oakland, California 94609, gwatson@chori.org, Tel.: +1 510 450-7665, Fax: +1 510 450-7910.

#### **CONFLICT of INTEREST**

The authors have no conflict of interest to disclose.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## 1. INTRODUCTION

Smith-Lemli-Opitz syndrome (SLOS, OMIM 270400, locus 11q13.4) was first described in 1964 [1] and shown much later to be an inborn error of cholesterol (C) biosynthesis [2, 3] that results in a broad range of physical dysmorphias and cognitive impairment [4]. The biochemical cause is deficient 3 $\beta$ -hydroxysterol-7-reductase (EC 1.3.1.21, 7-dehydrocholesterol reductase, DHCR7), which reduces the 7 bond in 7-dehydrocholesterol (7DHC) to form cholesterol in the last step of the Kandutsch-Russell cholesterol synthetic pathway [5]. As a result, cholesterol production decreases, and amounts of dehydro precursors of cholesterol, such as 7DHC and 8-dehydrocholesterol (8DHC), increase in tissues and serum [2, 3, 6]. Comparing the concentration of 7DHC in plasma or serum to control levels, as measured by gas chromatography/mass spectrometry (GC/MS) [7], is used to diagnose SLOS. Prenatal diagnosis is also possible by measurement of the characteristic dehydrosterols in amniotic fluid or chorionic villus cells [7–9], and fetal-derived dehydrosteroid derivatives in maternal urine or serum [10].

SLOS predominantly presents in Caucasian populations, with the incidence reported to be between 1:10,000 and 1:70,000 in northern and central Europe [11–14], and likely less than 1:100,000 in North America [15, 16]. The carrier frequency for the commonly found DHCR7 mutations predicts a much higher incidence rate, and it is possible that SLOS is under-diagnosed [15, 17] because the milder cases may be missed [18, 19], and the more severe cases may result in prenatal or neonatal death [13, 20, 21]. Currently, the only treatment is dietary cholesterol supplementation, and while this has been suggested to have positive biochemical and developmental benefits [22–25], pre-existing dysmorphias are irreversible and neurological outcomes are unchanged. In contrast to previous anecdotal evidence, a short-term, placebo controlled study [26] showed that supplemental exogenous cholesterol did not improve neurological outcome in SLOS children. Likely, this is because the blood brain barrier prevents circulating cholesterol from altering the sterol composition in the brain [27]. Because fetal development is highly dependent on endogenous cholesterol synthesis [28–32], treatment would ideally be administered prenatally in order to moderate otherwise irreversible symptoms; however, any such treatment remains to be developed.

Gene therapy is a largely unexplored treatment for this disorder that could address many of the shortcomings of dietary cholesterol supplementation. By importing a functional DHCR7 gene, patients could increase cholesterol and concomitantly decrease 7DHC. This should be doubly beneficial, firstly because sufficient cholesterol is needed for its multiple roles in metabolism, structure and regulation, and secondly because the accumulation of 7DHC can change the physical properties of cell membranes [27] and has deleterious effects when metabolized to oxidized derivatives [33]. Therefore, gene therapy has the potential to improve systemic and brain cholesterol synthesis, and if administered *in utero*, may even decrease the prevalence of fetal loss and ameliorate early deleterious effects.

Here we focus on systemic treatment of newborn and juvenile mice. In a previous study, we showed “proof of concept” for gene therapy in a mouse model for SLOS. Using a recombinant type-2 adeno-associated virus (AAV2) vector carrying a human *DHCR7* cDNA and a heterologous promoter, we achieved production of active DHCR7 enzyme and

increased cholesterol synthesis, as demonstrated by lowered serum 7DHC/C ratio [34]. Because the biochemical improvement was modest and complete normalization of cholesterol was not achieved, we hypothesized, and presently describe, that higher vector doses, a more efficient vector, and/or earlier treatment administration can yield a greater positive effect.

## 2. MATERIALS and METHODS

### 2.1. Animal husbandry

Animal work conformed to NIH guidelines and was approved by the Institutional Animal Care and Use Committee. All animals were maintained in an AAALAC certified facility and were fed a normal, cholesterol-free chow (Teklad irradiated rodent diet 2918: Harlan, Madison, WI).

### 2.2. Generation of experimental animals

Use of mutant mice and their breeding protocol was as previously described [35]. In brief, study animals were generated by crossing two separate mouse models of SLOS: a null mutant containing a partial deletion of *Dhcr7* ( ) [36] and a hypomorphic mutant containing a point mutation (T93M) [37]. /T93M mice were used for all experiments because they exhibit the most severe, yet still viable, phenotype. Mice with genotypes of T93M/T93M, /T93M and / show SLOS characteristics of increasing biochemical severity, with / being lethal [36, 37]. Mice heterozygous for the wild type allele, /+ and T93M/+, have a normal phenotype.

The /T93M mice exhibit classic SLOS symptoms, such as elevated 7DHC/C ratios in the serum and tissues, decreased size compared to wild-type littermates, and sporadic syndactyly. Littermates having the /T93M genotype were assigned to each experimental group (treated or control), and an effort was made to balance the two groups with respect to the initial average serum 7DHC/C ratio. Males and females were included in both groups, as no apparent correlation has been noted between gender and 7DHC/C ratios [34].

### 2.3. Preparation of AAV2 and AAV2/8 vectors

Vector construction, production and purification were as described previously [34]. Human *DHCR7* cDNA was cloned into the EcoRI site of the pV4.1c plasmid, which contained a CMV promoter/enhancer and AAV2 inverted terminal repeats. A woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) was included at the 3' untranslated end of the *DHCR7* to increase expression levels. AAV2-DHCR7 particles were produced in an adenovirus-free system by triple-transfecting HEK293 cells with plasmid pV4.1c-DHCR7, an AAV2 packaging plasmid, and a plasmid containing adenovirus helper genes [38]. For AAV2/8-DHCR7 particles, the procedure was the same except that the packaging plasmid (p5E18-VD2/8 kindly provided by James Wilson, University of Pennsylvania) contained an AAV2 rep gene fused to an AAV8 cap gene [39]. DNA packaged in capsid was purified by Optiprep gradient (Iodixanol) and 2 cesium chloride gradient centrifugations [40]. Finally, the viral vector was dialyzed against normal saline and the titer in vector genomes (vg) per

ml was established by quantitative PCR (AAV2-DHCR7 titer:  $5.7 \times 10^{12}$  vg/ml, AAV2/8-DHCR7 titer:  $5.8 \times 10^{12}$  vg/ml).

#### 2.4. Treatment of SLOS mice and serum collection

In an effort to match initial 7DHC/C ratios between treated and control groups, sterols were analyzed from blood collected from  $\Delta$ T93M newborns and juveniles prior to injection. From newborns, blood was collected from the temporal vein by inserting the bevel of a 29-gauge needle into the superficial temporal vein and lifting up slightly to allow a droplet of blood to pool. From mice 3 weeks and older, blood was collected from the retro-orbital sinus. Newborns were treated at 3 days of age (1 and 2 day old SLOS pups were too fragile for treatment) and, a single 60 $\mu$ l dose of AAV vector was injected intravenously via the superficial temporal vein. For juveniles (4 weeks old) a single 200 $\mu$ l dose was injected via the tail vein. Sham treated controls received comparable injections of saline. In the juvenile cohorts, blood was collected every week following injection to monitor serum 7DHC/C. For newborns, blood was not collected again until the mice were 3 weeks old, but was collected weekly thereafter. This was done because the temporal vein is no longer visible after the first post-natal week, and retro-orbital bleeding is not feasible until 3 weeks of age. All mice were weighed at the times of retro-orbital blood collection.

#### 2.5. Nucleic acid extraction and analysis

Anesthetized mice were euthanized at 13 or 14 weeks of age by exsanguination via cardiac puncture. Livers and brains were excised, immediately frozen in liquid nitrogen and stored at  $-80^{\circ}$  C until analysis. DNA and RNA extraction, PCR, RT-PCR and quantitative RT-PCR (SYBR Green detection in an ABI 7900 instrument) were as previously described [34]. A commercial primer pair specific for human *DHCR7* yielded a 123 base pair PCR product and a primer pair specific for mouse *Dhcr7* yielded a 125 base pair PCR product (Origene, Rockville, MD). For quantitative RT-PCR, mouse glyceraldehyde 3-phosphate dehydrogenase (mGAPDH) mRNA was also measured to provide an internal reference.

#### 2.6. Analysis of cholesterol and dehydrocholesterol by GC/MS

Sample preparation for serum, liver, and brain were the same as previously described [34]. An internal standard (stigmasterol) was added to the samples, which were then saponified. Afterwards, the samples were extracted and reacted with BSTFA to form the trimethylsilyl (TMS) derivatives. To prevent conversion of 7DHC to previtamin-D3, all tubes were protected from light by foil covers, and the entire procedure was conducted under minimum lighting conditions. Analysis was as previously described [34, 41] using an Agilent 5975C Gas Chromatography/Mass Spectrometry instrument with a HP-5MS column [35]. Calibration curves were prepared daily for each analytical batch by combining increasing amounts of the analytes with a fixed amount of stigmasterol, followed by derivatization [34]. In liver and serum samples, 8DHC levels were never significantly above background, so only 7DHC levels were used to calculate ratios to cholesterol. In brain samples levels of 8DHC were significant and ratios were calculated as (7DHCR + 8DHCR)/C.

## 2.7. Statistical Analysis

Because data did not meet the criteria for a normal distribution, they were subjected to nonparametric statistical analysis using the Mann-Whitney rank-sum test for each comparison at a given time point. In addition to single time point comparisons, multiple time point comparisons between treated and untreated groups were also subjected to statistical analysis. This allowed comparison across whole time curves and added statistical power. To compare curves for serum and weight data over time, the mixed random effects model for longitudinal analysis was used as previously described [34]. Since the raw data showed that the pattern of covariances were not constant, more traditional statistical analyses were not valid. On the other hand, mixed random models do not require this assumption and were therefore chosen for the analysis of our data. Differences having P values of 0.05 or less (two-tailed) were taken as significant.

## 3. RESULTS

### 3.1. Administration of vectors

For experiments described, all SLOS mice were compound heterozygotes carrying one null allele ( ) and one hypomorphic allele (T93M) of *Dhcr7* [37]. This provided the most severe yet still viable SLOS phenotype currently available in an animal model. To treat these mice, two vectors were utilized. Both contained the same DNA, which included a human *DHCR7* cDNA driven by a CMV promoter/enhancer, but one (AAV2-DHCR7) was packaged with type 2 capsid and the other (AAV2/8-DHCR7) with type 8 capsid. Experiments were conducted to compare the efficacy of AAV2 against AAV2/8, and to examine the effect of age on treatment. Three cohorts of experimental mice were established: 1) a cohort of 17 mice injected at 4 weeks of age (10 treated with  $1.1 \times 10^{12}$  vg AAV2-DHCR7 for an average dose of  $10^{14}$  vg/kg; 7 with saline alone), 2) a cohort of 16 mice injected at 4 weeks of age (8 treated with  $1.2 \times 10^{12}$  vg AAV2/8-DHCR7 for an average dose of  $10^{14}$  vg/kg; 8 with saline), and 3) a cohort of 15 mice injected at 3 days of age (8 treated with  $3.5 \times 10^{11}$  vg AAV2/8-DHCR7 for an average dose of  $2.5 \times 10^{14}$  vg/kg; 7 with saline).

### 3.2. *DHCR7* gene detection and mRNA expression

First, to confirm the presence or absence of vector DNA, liver DNA was subjected to PCR using primers specific for human *DHCR7*. In all three groups of experimental mice human *DHCR7* DNA was detected in the livers of vector treated, but not control mice. Then, to measure *DHCR7* mRNA, cDNA synthesized from liver mRNA was subjected to PCR using the human *DHCR7* specific primers. As a positive control, RT-PCR was also done using primers specific to the mouse *Dhcr7* gene transcript. Specificity of the human and mouse primer pairs and expression of human *DHCR7* mRNA only in the treated mice were established by running RT-PCR products on a gel (Fig. 1a). Levels of human *DHCR7* mRNA were then quantified by RT-qPCR using mouse GAPDH mRNA as an internal standard (Fig. 1b). Expression relative to the uniformly expressed mGAPDH gene transcript was calculated by dividing the concentration of h*DHCR7* mRNA by the concentration of mGAPDH mRNA. The h*DHCR7* gene expression in mice treated with AAV2/8-DHCR7 was significantly higher than in mice treated with AAV2-DHCR7 ( $P < 0.05$ ). For AAV2/8-

DHCR7, the expression in mice treated as newborns was greater than in mice treated as juveniles, although the criterion for statistical significance was not quite met ( $P = 0.07$ ).

### 3.3. 7DHC/C ratio in the serum, liver, and brain of treated mice

The ratio of 7DHC/C serves as a biochemical indication of SLOS severity. In the  $\Delta T93M$  mice this ratio was always elevated, whereas in normal mice ( $+/+$ ,  $/+$  or  $T93M/+$ ) it was not measurably above zero. Thus, a goal of treatment is to minimize this ratio.

After treatment the ratio of 7DHC/C was measured in the sera of all mice at regular intervals. GC/MS was used to measure sterol concentrations and calculate ratios of 7DHC/C, and the results for the juvenile and newborn cohorts are shown in Fig. 2. As previously described [34], serum 7DHC/C ratios in treated and especially untreated SLOS mice varied considerably with age. In all three cohorts, the trend was for treated mice to have lower 7DHC/C ratios than their untreated littermates. In the AAV2-DHCR7 juvenile cohort the ratio of 7DHC/C in the serum of treated mice was apparently lower than in controls, but statistically significant at only 2 time points (Fig. 2a), whereas in the AAV2/8-DHCR7 juvenile cohort, treatment lowered the ratio with statistical significance at 5 time points (Fig. 2b). In the newborn treated cohort, the ratio of 7DHC/C was lower than in controls with statistical significance at 6 time points (Fig. 2c). To compare treated vs. control over the whole curve rather than at single time points, the mixed random effects model was employed. This more comprehensive analysis showed that each of the treatments had a statistically significant effect in lowering 7DHC/C ratios (AAV2 juveniles,  $P = 0.025$ ; AAV2/8 juveniles,  $P < 0.001$ ; AAV2/8 newborns,  $P < 0.001$ ). Adjusting for sex did not affect these differences.

The ratio of 7DHC/C was also measured in the liver and brain after the animals were sacrificed. Although treatment resulted in an apparent decrease in liver ratios for all 3 cohorts, statistical significance in the AAV2-DHCR7 juvenile cohort was compromised by high variability among the untreated controls. In the juvenile and newborn cohorts treated with AAV2/8-DHCR7 the liver 7DHC/C ratios were significantly lower ( $P = 0.03$  in each case) in the treated mice as compared to their littermate controls (Fig. 3a). Notably, there were no detectable differences in brain sterols between treated and untreated mice for any of the three cohorts (Fig. 3b)

### 3.4. Gene therapy and growth rate

To determine if gene therapy was able to alter physical outcomes, all animals were weighed once a week at the time of serum sampling. Because the SLOS mice tend to be smaller than their wild-type siblings [37] and because there was considerable animal-to-animal variation, relative rate of weight gain was used as an indicator of growth. This was calculated individually for each animal by dividing the weight at each week by the initial weight to yield the percent weight gain as a function of time (Fig. 4). The AAV2/8-DHCR7 treated mice, both newborns and juveniles, gained weight more rapidly than their sham-treated controls, while the AAV2-DHCR7 treated juveniles did not. Again, whole curves rather than individual time points were analyzed using the random effects model to make longitudinal comparisons. Both AAV2/8-DHCR7 treatments had highly significant effects on weight

gain ( $P < 0.001$ ). Adjusting for sex did not compromise the statistical significance of treatment even though males tended to grow faster than females (both treated and untreated).

For the AAV2/8-DHCR7 juvenile cohort, normal phenotype (T93M/+ genotype) littermates were also weighed weekly at 4 to 14 weeks of age. Although these mice were bigger than their SLOS littermates at both the beginning and throughout the time period, their relative rates of growth were indistinguishable from their untreated SLOS siblings (data not shown). That is, over this time period, the two groups grew in parallel. In contrast, the relative rate of growth for the treated SLOS mice was faster than normal, suggesting that treatment had a “catch up” effect on growth.

Compared to their respective littermate controls, newborn mice treated with AAV2/8-DHCR7 did not gain weight faster than juvenile mice treated with the same vector (compare Fig. 4b with 4c). It should be noted, however, that the newborn group might have already had an enhanced growth rate prior to its index weight at 3 weeks.

#### 4. DISCUSSION

Previously, we showed that gene transfer has the potential to alter cholesterol synthesis in a mouse model of SLOS, although the demonstrated effect was quite modest [34]. Here we report the following: 1) confirmation and extension of initial observations showing that gene therapy can significantly decrease the ratio of 7DHC/C in both the liver and serum; 2) comparison of the efficacy of two AAV vectors; 3) the effect of age at the time of treatment; 4) demonstration of a positive effect on growth rate.

Using both AAV2 and AAV2/8 vectors, the human *DHCR7* gene was delivered and expressed in the liver, the primary target of these vectors following intravenous administration in mice [39, 42–44]. The dose used was sufficient to increase liver cholesterol and decrease 7DHC, which indicates that a functional enzyme was being produced and was actively converting 7DHC to cholesterol; this benefits the animal by reducing the dual burdens of cholesterol deficiency and 7DHC toxicity. (Direct measurements of *DHCR7* enzyme activity were not done because cell disruption tends to inactivate this membrane-bound protein.) Since the liver is the principal systemic source of cholesterol, we hypothesized that local correction of cholesterol synthesis would have systemic effects, and this was evidenced by a strong correlation between the ratios of 7DHC/C in the serum and in the liver for each animal ( $r^2 = 0.90$ , data not shown). Thus, we suggest that transduced liver cells might act as depots of *DHCR7* activity and that 7DHC, either endogenous or imported, could be converted to cholesterol and then exported to other areas of the body as needed. Rigorous confirmation of this idea remains to be demonstrated. As expected, however, there was no significant change in brain sterols, because the blood brain barrier limits the uptake of both viral vectors [45] and circulating cholesterol [46]. Preliminary (unpublished) results suggest that the blood brain barrier can be circumvented by an alternate route of vector administration, namely intrathecal injection, which we have used successfully for other genetic diseases [45, 47]. This avenue is currently being pursued. Another possibility would be to use a different vector that is more effective in crossing the blood brain barrier, such as AAV 9 [48].

The greater reduction of the serum 7DHC/C ratio in juvenile mice treated with AAV2/8-DHCR7 suggests that the AAV2/8 vector was more efficient than the AAV2 vector for increasing systemic cholesterol. This is consistent with reports that AAV2/8 vectors better transduce hepatocytes than AAV2 vectors [39, 42, 49, 50]. Using AAV2/8-DHCR7, but not AAV2-DHCR7, the increase in systemic cholesterol was sufficient to alter growth outcomes, as both juvenile and newborn animals treated with the AAV2/8 vector grew faster. In the case of treated newborns, relative growth was indexed to the weight at 3 weeks of age (when regular blood collection began) rather than the time of treatment. Thus, these animals may have already partially overcome their delayed growth rates; nevertheless, they continued to grow more rapidly than their sham-treated littermates after weaning.

Administering gene therapy to both newborn mice and 4-week-old mice allowed us to evaluate the role of age in treatment effectiveness. When administered to either newborns or juveniles, gene therapy was persistent until at least 3 months of age. At the end of the experiments, treatment of newborns was 33% to 45% more effective by three biochemical criteria, but the differences were statistically marginal ( $P = 0.07$  for hDHCR7 mRNA in liver;  $P = 0.06$  for DHC/C ratio in liver;  $P = 0.03$  for DHC/C in serum). Because of their size, newborns received a lower absolute dose of AAV2/8-DHCR7, but a higher relative dose (vector particles per body weight) than the mice treated as juveniles. This, in addition to age alone, could also contribute to the observed effectiveness of AAV2/8-DHCR7. The effectiveness of newborn treatment was somewhat surprising as it has been suggested that, for the long term, treating newborns is less effective than treating adults because episomal vector genomes in transduced cells are diluted by repeated cell replications [51]. But, it has also been observed that in treated newborns, a small fraction of vector genomes can integrate stably and result in persistent transgene expression [52]. Considering the potential advantages of earlier intervention, our results suggest that for SLOS there may be benefits from early administration in spite of vector genome dilution.

#### 4.1. Conclusions

Gene therapy improved systemic cholesterol synthesis in juveniles and newborns of a mouse model for SLOS. Importantly, although complete normalization of sterol metabolism was not achieved, there was still a positive effect on physical outcome, as evidenced by improvements in growth rate. This supports two clinically relevant ideas: (1) Treatment does not have to completely normalize cholesterol in order to provide tangible benefit. (2) In spite of defects that arise early in development and may not be reversible, treatment of SLOS newborns and even juveniles still has the potential to provide some physiological improvement. Perhaps with even earlier treatment *in utero*, still greater normalization of cholesterol metabolism and more effective amelioration of SLOS symptoms can be achieved.

#### Acknowledgments

This work was supported by US National Institutes of Health Grant R01HD053036 to C. Shackleton and G. Watson. Dr. Serra was awarded a Beatriu de Pinós postdoctoral fellowship from Generalitat de Catalunya, Spain.




## References

1. Smith DW, Lemli L, Opitz JM. A Newly Recognized Syndrome of Multiple Congenital Anomalies. *J Pediatr.* 1964; 64:210–217. [PubMed: 14119520]
2. Irons M, Elias ER, Salen G, Tint GS, Batta AK. Defective cholesterol biosynthesis in Smith-Lemli-Opitz syndrome. *Lancet.* 1993; 341:1414. [PubMed: 7684480]
3. Tint GS, Irons M, Elias ER, Batta AK, Frieden R, Chen TS, Salen G. Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. *N Engl J Med.* 1994; 330:107–113. [PubMed: 8259166]
4. Porter FD, Herman GE. Malformation syndromes caused by disorders of cholesterol synthesis. *J Lipid Res.* 2011; 52:6–34. [PubMed: 20929975]
5. Kandutsch AA, Russell AE. Preputial gland tumor sterols. 3. A metabolic pathway from lanosterol to cholesterol. *J Biol Chem.* 1960; 235:2256–2261. [PubMed: 14404284]
6. Batta AK, Tint GS, Shefer S, Abuelo D, Salen G. Identification of 8-dehydrocholesterol (cholesta-5,8-dien-3 beta-ol) in patients with Smith-Lemli-Opitz syndrome. *J Lipid Res.* 1995; 36:705–713. [PubMed: 7616117]
7. Kelley RI. Diagnosis of Smith-Lemli-Opitz syndrome by gas chromatography/mass spectrometry of 7-dehydrocholesterol in plasma, amniotic fluid and cultured skin fibroblasts. *Clin Chim Acta.* 1995; 236:45–58. [PubMed: 7664465]
8. Tint GS, Abuelo D, Till M, Cordier MP, Batta AK, Shefer S, Honda A, Honda M, Xu G, Irons M, Elias ER, Salen G. Fetal Smith-Lemli-Opitz syndrome can be detected accurately and reliably by measuring amniotic fluid dehydrocholesterols. *Prenat Diagn.* 1998; 18:651–658. [PubMed: 9706645]
9. Griffiths WJ, Wang Y, Karu K, Samuel E, McDonnell S, Hornshaw M, Shackleton C. Potential of sterol analysis by liquid chromatography-tandem mass spectrometry for the prenatal diagnosis of Smith-Lemli-Opitz syndrome. *Clin Chem.* 2008; 54:1317–1324. [PubMed: 18556335]
10. Shackleton CH, Marcos J, Palomaki GE, Craig WY, Kelley RI, Kratz LE, Haddow JE. Dehydrosteroid measurements in maternal urine or serum for the prenatal diagnosis of Smith-Lemli-Opitz syndrome (SLOS). *Am J Med Genet A.* 2007; 143A:2129–2136. [PubMed: 17702049]
11. Ryan AK, Bartlett K, Clayton P, Eaton S, Mills L, Donnai D, Winter RM, Burn J. Smith-Lemli-Opitz syndrome: a variable clinical and biochemical phenotype. *J Med Genet.* 1998; 35:558–565. [PubMed: 9678700]
12. Bzduch V, Behulova D, Skodova J. Incidence of Smith-Lemli-Opitz syndrome in Slovakia. *Am J Med Genet.* 2000; 90:260. [PubMed: 10678669]
13. Kelley RI. A new face for an old syndrome. *Am J Med Genet.* 1997; 68:251–256. [PubMed: 9024554]
14. Lowry RB, Yong SL. Borderline normal intelligence in the Smith-Lemli-Opitz (RSH) syndrome. *Am J Med Genet.* 1980; 5:137–143. [PubMed: 7395908]
15. Nowaczyk MJ, Zeesman S, Waye JS, Douketis JD. Incidence of Smith-Lemli-Opitz syndrome in Canada: results of three-year population surveillance. *J Pediatr.* 2004; 145:530–535. [PubMed: 15480380]
16. Craig WY, Haddow JE, Palomaki GE, Kelley RI, Kratz LE, Shackleton CH, Marcos J, Stephen Tint G, MacRae AR, Nowaczyk MJ, Kloza EM, Irons MB, Roberson M. Identifying Smith-Lemli-Opitz syndrome in conjunction with prenatal screening for Down syndrome. *Prenat Diagn.* 2006; 26:842–849. [PubMed: 16832833]
17. Battaile KP, Battaile BC, Merkens LS, Maslen CL, Steiner RD. Carrier frequency of the common mutation IVS8-1G>C in DHCR7 and estimate of the expected incidence of Smith-Lemli-Opitz syndrome. *Mol Genet Metab.* 2001; 72:67–71. [PubMed: 11161831]
18. Langius FA, Waterham HR, Romeijn GJ, Oostheim W, de Barse MM, Dorland L, Duran M, Beemer FA, Wanders RJ, Poll-The BT. Identification of three patients with a very mild form of Smith-Lemli-Opitz syndrome. *Am J Med Genet A.* 2003; 122A:24–29. [PubMed: 12949967]
19. Nowaczyk MJ, Whelan DT, Hill RE. Smith-Lemli-Opitz syndrome: phenotypic extreme with minimal clinical findings. *Am J Med Genet.* 1998; 78:419–423. [PubMed: 9714007]


20. Nowaczyk MJ, Waye JS, Douketis JD. DHCR7 mutation carrier rates and prevalence of the RSH/Smith-Lemli-Opitz syndrome: where are the patients? *Am J Med Genet A*. 2006; 140:2057–2062. [PubMed: 16906538]
21. Opitz JM, Gilbert-Barnes E, Ackerman J, Lowichik A. Cholesterol and development: the RSH (“Smith-Lemli-Opitz”) syndrome and related conditions. *Pediatr Pathol Mol Med*. 2002; 21:153–181. [PubMed: 11942534]
22. Nwokoro NA, Mulvihill JJ. Cholesterol and bile acid replacement therapy in children and adults with Smith-Lemli-Opitz (SLO/RSH) syndrome. *Am J Med Genet*. 1997; 68:315–321. [PubMed: 9024566]
23. Elias ER, Irons MB, Hurley AD, Tint GS, Salen G. Clinical effects of cholesterol supplementation in six patients with the Smith-Lemli-Opitz syndrome (SLOS). *Am J Med Genet*. 1997; 68:305–310. [PubMed: 9024564]
24. Irons M, Elias ER, Abuelo D, Bull MJ, Greene CL, Johnson VP, Keppen L, Schanen C, Tint GS, Salen G. Treatment of Smith-Lemli-Opitz syndrome: results of a multicenter trial. *Am J Med Genet*. 1997; 68:311–314. [PubMed: 9024565]
25. Linck LM, Lin DS, Flavell D, Connor WE, Steiner RD. Cholesterol supplementation with egg yolk increases plasma cholesterol and decreases plasma 7-dehydrocholesterol in Smith-Lemli-Opitz syndrome. *Am J Med Genet*. 2000; 93:360–365. [PubMed: 10951458]
26. Tierney E, Conley SK, Goodwin H, Porter FD. Analysis of short-term behavioral effects of dietary cholesterol supplementation in Smith-Lemli-Opitz syndrome. *Am J Med Genet A*. 2010; 152A:91–95. [PubMed: 20014133]
27. Bjorkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. *Arterioscler Thromb Vasc Biol*. 2004; 24:806–815. [PubMed: 14764421]
28. Jurevics HA, Kidwai FZ, Morell P. Sources of cholesterol during development of the rat fetus and fetal organs. *J Lipid Res*. 1997; 38:723–733. [PubMed: 9144087]
29. Tint GS, Yu H, Shang Q, Xu G, Patel SB. The use of the Dhcr7 knockout mouse to accurately determine the origin of fetal sterols. *J Lipid Res*. 2006; 47:1535–1541. [PubMed: 16651660]
30. Edmond J, Korsak RA, Morrow JW, Torok-Both G, Catlin DH. Dietary cholesterol and the origin of cholesterol in the brain of developing rats. *J Nutr*. 1991; 121:1323–1330. [PubMed: 1880610]
31. Jurevics H, Morell P. Cholesterol for synthesis of myelin is made locally, not imported into brain. *J Neurochem*. 1995; 64:895–901. [PubMed: 7830084]
32. Turley SD, Burns DK, Rosenfeld CR, Dietschy JM. Brain does not utilize low density lipoprotein-cholesterol during fetal and neonatal development in the sheep. *J Lipid Res*. 1996; 37:1953–1961. [PubMed: 8895061]
33. Gaoua W, Chevy F, Roux C, Wolf C. Oxidized derivatives of 7-dehydrocholesterol induce growth retardation in cultured rat embryos: a model for antenatal growth retardation in the Smith-Lemli-Opitz syndrome. *J Lipid Res*. 1999; 40:456–463. [PubMed: 10064734]
34. Matabosch X, Ying L, Serra M, Wassif CA, Porter FD, Shackleton C, Watson G. Increasing cholesterol synthesis in 7-dehydrosterol reductase (DHCR7) deficient mouse models through gene transfer. *J Steroid Biochem Mol Biol*. 2010; 122:303–309. [PubMed: 20800683]
35. Serra M, Matabosch X, Ying L, Watson G, Shackleton C. Hair and skin sterols in normal mice and those with deficient dehydrosterol reductase (DHCR7), the enzyme associated with Smith-Lemli-Opitz syndrome. *J Steroid Biochem Mol Biol*. 2010; 122:318–325. [PubMed: 20804844]
36. Wassif CA, Zhu P, Kratz L, Krakowiak PA, Battaile KP, Weight FF, Grinberg A, Steiner RD, Nwokoro NA, Kelley RI, Stewart RR, Porter FD. Biochemical, phenotypic and neurophysiological characterization of a genetic mouse model of RSH/Smith-Lemli-Opitz syndrome. *Hum Mol Genet*. 2001; 10:555–564. [PubMed: 11230174]
37. Correa-Cerro LS, Wassif CA, Kratz L, Miller GF, Munasinghe JP, Grinberg A, Fliesler SJ, Porter FD. Development and characterization of a hypomorphic Smith-Lemli-Opitz syndrome mouse model and efficacy of simvastatin therapy. *Hum Mol Genet*. 2006; 15:839–851. [PubMed: 16446309]
38. Matsushita T, Elliger S, Elliger C, Podsakoff G, Villarreal L, Kurtzman GJ, Iwaki Y, Colosi P. Adeno-associated virus vectors can be efficiently produced without helper virus. *Gene Ther*. 1998; 5:938–945. [PubMed: 9813665]

39. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. *Proc Natl Acad Sci U S A*. 2002; 99:11854–11859. [PubMed: 12192090]
40. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, Summerford C, Samulski RJ, Muzyczka N. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. *Gene Ther*. 1999; 6:973–985. [PubMed: 10455399]
41. Marcos J, Shackleton CH, Buddhikot MM, Porter FD, Watson GL. Cholesterol biosynthesis from birth to adulthood in a mouse model for 7-dehydrosterol reductase deficiency (Smith-Lemli-Opitz syndrome). *Steroids*. 2007; 72:802–808. [PubMed: 17714750]
42. Nakai H, Fuess S, Storm TA, Muramatsu S, Nara Y, Kay MA. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. *J Virol*. 2005; 79:214–224. [PubMed: 15596817]
43. Watson GL, Sayles JN, Chen C, Elliger SS, Elliger CA, Raju NR, Kurtzman GL, Podsakoff GM. Treatment of lysosomal storage disease in MPS VII mice using a recombinant adeno-associated virus. *Gene Therapy*. 1998; 5:1642–1649. [PubMed: 10023443]
44. Sharma V, Beckstead JA, Simonsen JB, Nelbach L, Watson G, Forte TM, Ryan RO. Gene transfer of apolipoprotein A-V improves the hypertriglyceridemic phenotype of apoA5 (–/–) mice. *Arterioscler Thromb Vasc Biol*. 2013; 33:474–480. [PubMed: 23329134]
45. Watson G, Bastacky J, Belichenko P, Buddhikot M, Jungles S, Vellard M, Mobley WC, Kakkis E. Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice. *Gene Ther*. 2006; 13:917–925. [PubMed: 16482204]
46. Dietschy JM. Central nervous system: cholesterol turnover, brain development and neurodegeneration. *Biol Chem*. 2009; 390:287–293. [PubMed: 19166320]
47. Elliger SS, Elliger CA, Lang C, Watson GL. Enhanced secretion and uptake of beta-glucuronidase improves adeno-associated viral-mediated gene therapy of mucopolysaccharidosis type VII mice. *Mol Ther*. 2002; 5:617–626. [PubMed: 11991753]
48. Dayton RD, Wang DB, Klein RL. The advent of AAV9 expands applications for brain and spinal cord gene delivery. *Expert Opin Biol Ther*. 2012; 12:757–766. [PubMed: 22519910]
49. Thomas CE, Storm TA, Huang Z, Kay MA. Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. *J Virol*. 2004; 78:3110–3122. [PubMed: 14990730]
50. Grimm D, Pandey K, Nakai H, Storm TA, Kay MA. Liver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype. *J Virol*. 2006; 80:426–439. [PubMed: 16352567]
51. Cunningham SC, Dane AP, Spinoulas A, Logan GJ, Alexander IE. Gene delivery to the juvenile mouse liver using AAV2/8 vectors. *Mol Ther*. 2008; 16:1081–1088. [PubMed: 18414478]
52. Inagaki K, Piao C, Kotchey NM, Wu X, Nakai H. Frequency and spectrum of genomic integration of recombinant adeno-associated virus serotype 8 vector in neonatal mouse liver. *J Virol*. 2008; 82:9513–9524. [PubMed: 18614641]




**Figure 1.**

Expression of *hDHCR7* mRNA in livers of treated mice. (a) RT-PCR was performed on liver RNA. Lanes 1 and 2 are from mouse A, lanes 3 and 4 are from mouse B etc. In odd numbered lanes primers to the *hDHCR7* gene (123 base pair PCR product) were used, and in even numbered lanes primers to the mouse homologue (*mDhcr7*, 125 base pair product) were used. *mDhcr7* was expressed in both control (A, B, C) and AAV2/8-DHCR7 treated (D, E, F) mice. *hDHCR7* was expressed only in the treated mice. Qualitatively similar results were seen from all treated and control mice. (b) Levels of *hDHCR7* mRNA expression determined by quantitative RT-PCR. Each bar represents the average relative mRNA expression  $\pm$  SEM. Relative mRNA expression was calculated by dividing the concentration of *hDHCR7* mRNA by the concentration of *mGAPDH* mRNA. The *hDHCR7* expression in mice treated with AAV vector was significantly higher than background levels in sham-treated controls (AAV2-DHCR7 Juveniles:  $P = 0.03$ ; AAV2/8-DHCR7 Juveniles:  $P < 0.01$ ; AAV2/8-DHCR7 Newborns:  $P < 0.01$ ).




**Figure 2.** Weekly 7DHC/C ratios in serum comparing treated and sham-treated littermates. (a) AAV2-DHCR7 treated juvenile cohort. (b) AAV2/8-DHCR7 treated juvenile cohort. (c) AAV2/8-DHCR7 treated newborn cohort. \* denotes statistically significant ( $P < 0.05$ ) differences in 7DHC/C ratio.



**Figure 3.**

Systemic treatment lowers DHC/C ratios in liver but not brain. (a) 7DHC/C ratios were determined for liver; (b) [7DHC + 8DHC]/C ratios were determined for brain. Because 8DHC levels in liver were not measurably above background, only 7DHC measurements were used to calculate DHC/C ratios. In brain 8DHC levels were significant and were therefore included in DHC/C ratios. Ratios shown are means  $\pm$  SEM.



**Figure 4.**

Change in rate of weight gain following treatment. The weight of each animal at each time point was compared to its own weight at the time of injection or at the time of weaning. This provided cumulative % weight gains at weekly intervals. (a) Juveniles treated with AAV2-DHCR7 with weight gain indexed to the time of injection at 4 weeks of age (no statistical difference between treated and untreated). (b) Juveniles treated with AAV2/8-DHCR7 with weight gain indexed to time of injection at 4 weeks of age (treatment difference,  $P < 0.001$ ). (c) Newborns treated with AAV2/8-DHCR7 with weight indexed to the time of weaning at 3 weeks of age (treatment difference,  $P < 0.001$ ). Statistical comparisons of treated vs. littermate controls employed the mixed random effects model for longitudinal analysis.